Facebook
Twitter
LinkedIn
ForwardCAR T Cell Therapy for Cancer: The Next Generation - Enduring
Medical staff requested a series of lectures on the landscape of cancer care. Perspectives from thought leaders helps to revitalize the medical staff and develop innovative ideas on ways they can improve and impact patient care as well as research methods and technology, in addition to creating connections which may result in the eventual treatment options which may cure cancer.
Target Audience
The activity content is oriented to address the educational needs of physicians, nurses and all healthcare professionals interested in the subject matter.
Learning Objectives
- Define the concept of CAR T cell therapy for cancer and recognize barriers to CAR T cell therapy of cancer including T cell persistence, antigen escape, and the immune suppressive tumor microenvironment.
- Recognize novel CAR T cell designs utilized to optimize anti-cancer efficacy of this novel approach as well as how these armored CAR T cell designs may bridge the gap from liquid to solid tumors.
Additional Information
| Attachment | Size |
|---|---|
 AB 1195 & 241 Bibliography_Renier Brentjens, MD, PhD | 168.49 KB |
This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.
As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months, including financial relationships of a spouse that could create a conflict of interest. Any potential conflicts relative to the previous disclosure have been resolved.
Presenter: Dr. Renier Brentjens has indicated the following disclosures: Receives Grant/Research Support from Juno Therapeutics; is/was a Consultant for Atara Biotherapeutics, Inc., and Gracell Biotechnologies (no longer active); and has Other Financial/Material Interests in Caribou Biosciences, Juno Therapeutics, and Sanofi (royalties & patents).
City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.
CAR T Cell Therapy for Cancer: The Next Generation - Enduring has received no commercial support.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hour toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this CAR T Cell Therapy for Cancer: The Next Generation - Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance
You must be logged in to access this Enduring.
If you are a New User, please create an account first, by clicking on "Register".
Once Logged in:
Click on "Start Activity" to access the educational content for this Enduring activity.